7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 
      
    		                                
      operating activities
    		                                
      net income/
    		                                
      adjustments to reconcile net income/(loss) to net cash from operating activities:
    		                                
      share-based compensation expense
    		28,186,000 27,197,000 27,374,000 26,314,000 27,475,000 29,990,000 30,349,000 26,219,000 21,625,000 29,278,000 28,823,000 24,241,000 23,541,000 22,530,000 20,773,000 19,312,000 17,194,000 17,722,000 16,439,000 12,494,000 12,099,000 11,489,000 9,294,000 7,107,068 5,295,152 4,183,221 4,558,588 1,828,617 2,050,924 2,243,527 1,610,188 4,164,340 
      loss on extinguishment of development liability
    		   0 0                            
      depreciation expense
    		339,000 446,000 446,000 447,000 457,000 449,000 444,000 476,000 462,000 425,000 421,000 388,000 401,000 386,000 377,000 373,000 282,000 442,000 282,000 267,000 190,000 95,000 85,000 86,713 65,549 46,918 40,503      
      amortization of discounts for credit facility
    		556,000 534,000 512,000 508,000 581,000                            
      amortization of discounts for convertible notes
    		80,000 80,000 79,000 79,000 77,000 77,000 76,000                          
      accretion of discount to development liability
    		   0 0 2,870,000 6,066,000 6,505,000 6,413,000 6,445,000 6,633,000 6,864,000 6,717,000 6,623,000 6,713,000                  
      changes in operating assets and liabilities:
    		                                
      accounts receivable
    		-131,403,000 21,118,000 29,680,000 14,085,000 25,421,000 -36,575,000 -61,415,000 -37,173,000 -58,356,000 -79,408,000 -23,778,000 365,000 -574,000 -1,189,000 3,773,000 -7,485,000 -1,899,000                
      inventory
    		5,402,000 -26,008,000 13,997,000 10,021,000 8,655,000 -14,510,000 -14,921,000 -47,816,000 4,671,000 -17,646,000 144,000 -25,961,000 -11,302,000 -15,601,000 -16,533,000 -14,640,000 2,054,000                
      prepaid assets
    		-2,384,000 7,953,000 -18,726,000 5,398,000 5,190,000 14,170,000 -4,338,000 5,811,000 -10,216,000 2,642,000 -107,000 -5,987,000 -8,882,000 3,056,000 334,000 -7,625,000 1,611,000 -1,654,000 -5,819,000 235,000 6,626,000 4,881,000 -3,004,000 -5,059,719 -765,742 6,532,304 3,824,196 -7,478,756 -5,998,668 -2,735,685 -3,062,009  
      other current assets
    		9,787,000 -6,838,000 -1,307,000 142,000 612,000 -658,000 10,697,000 8,262,000 -3,865,000 7,538,000 2,308,000 -12,521,000 3,232,000 44,537,000 -2,312,000 -47,605,000 10,988,000 -69,000 -4,242,000 -25,657,000 197,000 -153,000 -671,000 1,171,628 2,155,786 -3,064,915 24,854 -296,210 -20,279 195,354 -188,226 1,936,041 
      other assets
    		-4,440,000 61,000 198,000 786,000 225,000 -404,000 98,000 -3,111,000 -166,000 8,000 14,969,000 1,605,000 128,000 123,000 15,634,000 -8,826,000 -6,714,000 -9,188,000 11,946,000 -17,341,000 -1,000 -58,000 -460,000 -202,771 -28,952 -45,141 -45,925 -881,359    -7,800 
      right-of-use assets and lease liabilities
    		-113,000 215,000 7,000 -270,000 164,000 -55,000 -116,000                          
      accounts payable
    		-15,638,000 -1,045,000 16,711,000 1,488,000 -1,158,000 11,489,000 -10,730,000 19,620,000 -9,601,000 -3,995,000 -5,854,000 23,126,000 -7,028,000 8,962,000 -6,371,000 13,700,000 83,000 874,000 -4,170,000 -2,446,000 792,000 6,837,000 -5,237,000 -3,433,391 -2,008,290 1,894,386 1,906,521 4,792,625 325,080 547,959 921,805 -521,548 
      accrued expenses
    		7,075,000 22,883,000 -30,156,000   22,022,000 -26,330,000 11,851,000 20,034,000 26,536,000 -23,471,000 14,952,000 -3,977,000 -20,939,000 3,652,000 31,700,000 -64,611,000 65,321,000 -42,802,000 50,999,000 13,617,000 421,000 -9,991,000 24,908,739 10,145,204 12,635,167 2,764,408 -5,461,504 5,465,051 2,411,377 -180,904 -46,180 
      other current liabilities
    		                                
      other liabilities
    		            367,000 363,000 1,208,000         -250,000 0 15,067 76,150      
      net cash provided by/(used in) operating activities
    		                                
      investing activities
    		                                
      purchase of property and equipment
    		-148,000 -49,000 -8,000 -20,000 0 -90,000 -293,000 -95,000 -47,000 -372,000 -259,000 -851,000 -196,000 -391,000 -86,000 -19,000 -352,000 -248,000 -484,000 -711,000 -3,738,000 -538,000 -435,000 -155,786 -470,047 -192,378 -875,111      
      net cash from investing activities
    		-148,000 -49,000 -8,000 -20,000 0 -90,000 -293,000 4,000 -47,000 -372,000 -259,000 124,129,000 124,784,000 82,929,000 -271,949,000 84,980,000 179,649,000 129,752,000 -146,765,000 -91,000 198,763,000 -287,807,000 -227,854,000 -155,786 -470,047 -192,378 -875,111      
      financing activities
    		                                
      proceeds from credit facility
    		   0 0                            
      payment of issuance cost for credit facility
    		   -5,625,000 0                            
      repayment of development liability
    		   0 0                            
      proceeds from settlement of capped call
    		   0 0 0 98,763,000                          
      proceeds from exercise of stock options
    		797,000 4,367,000 281,000 321,000 2,556,000 1,962,000 9,477,000 25,465,000 5,757,000 22,334,000 17,718,000  10,639,000 4,770,000 4,000,000  2,481,000 7,062,000 2,588,000  1,126,000 1,355,000 1,674,000  929,710 1,262,162 192,005  114,989 275,749 225,361  
      proceeds from issuance of common stock under employee stock purchase plan
    		0                                
      payments of employee tax withholding related to equity-based compensation
    		-4,000 0 -7,000 -15,000 -14,000 0 -28,000   -28,000 -10,999,000 -1,727,000 -1,003,000 -536,000 -2,416,000 -237,000 -361,000 -234,000 -956,000              
      net cash from financing activities
    		793,000 6,558,000 274,000 -4,000,000 2,542,000 42,487,000 108,212,000 -3,913,000 5,746,000 1,560,000 391,106,000 -15,946,000 9,636,000 -4,735,000 376,704,000 383,958,000 2,120,000 4,526,000 1,632,000 6,317,000 926,000 281,668,000 403,267,000 209,610 198,949,710 40,963,913 148,418,251 115,657 -38,434 131,603,440 222,697 178,040,485 
      effect of exchange rate changes on cash, cash equivalents and restricted cash
    		22,000 685,000 359,000 -965,000 173,000 342,000 -209,000  -458,000 -47,000 56,000  -310,000 -429,000 64,000  -172,000 -241,000 -1,611,000  -1,646,000 132,000 -152,000          
      net increase in cash, cash equivalents and restricted cash
    		   14,375,000 36,811,000 34,400,000 -25,273,000  -163,844,000 -149,014,000 213,283,000    -6,741,000  12,972,000 5,349,000 -300,058,000  98,219,000 -100,301,000 66,912,000          
      cash, cash equivalents and restricted cash at beginning of period
    		0 0 412,612,000 0 0 0 352,299,000 -1,000 0 0 553,075,000 0 0 0 641,755,000 0 0 0 567,045,000 0 0 0 351,985,000          
      cash, cash equivalents and restricted cash at end of period
    		109,135,000 11,639,000 359,827,000 14,375,000 36,811,000 34,400,000 327,026,000 -101,201,000 -163,844,000 -149,014,000 766,358,000 -32,374,000 -20,307,000 -29,259,000 635,014,000 356,447,000 12,972,000 5,349,000 266,987,000 150,230,000 98,219,000 -100,301,000 418,897,000          
      reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:
    		                                
      cash and cash equivalents
    		109,135,000 11,643,000 358,393,000  36,777,000 34,164,000 325,923,000  -163,845,000 -148,824,000 765,083,000  -20,300,000 -28,967,000 633,456,000  12,981,000 5,329,000 265,435,000  98,212,000 -100,533,000 417,881,000          
      restricted cash
    		0 -4,000 1,434,000  34,000 236,000 1,103,000  1,000 -190,000 1,275,000  -7,000 -292,000 1,558,000  -9,000 20,000 1,552,000  7,000 232,000 1,016,000          
      total cash, cash equivalents, and restricted cash
    		109,135,000 11,639,000 359,827,000  36,811,000 34,400,000 327,026,000  -163,844,000 -149,014,000 766,358,000  -20,307,000 -29,259,000 635,014,000  12,972,000 5,349,000 266,987,000  98,219,000 -100,301,000 418,897,000          
      supplemental disclosures
    		                                
      cash paid for interest
    		20,796,000 0 11,092,000  12,497,000 5,306,000 1,643,000  1,643,000 0 1,643,000  1,643,000 0 3,360,000  3,372,000 0 6,893,000  9,100,000 0 3,829,000 28,383 230,521 140,000 588,473 477,639     
      cash paid for income taxes
    		40,000 666,000 141,000      194,000 134,000 250,000  0                    
      lease assets obtained in exchange for operating lease liabilities
    		                                
      issuance costs for credit facility incurred but not yet paid
    		                                
      net income
    		 -42,151,000 -92,225,000 -36,353,000 -57,445,000 -37,657,000 -66,423,000 -88,576,000 -140,237,000 -122,037,000 -177,778,000 -165,991,000 -191,269,000 -155,977,000 -138,935,000 -147,933,000 -195,571,000 -219,191,000 -183,659,000 78,265,000 -135,700,000 -118,617,000 -168,822,000 -113,217,423 -69,824,659 -71,090,164 -50,574,367 -36,459,474 -35,972,114 -33,334,302 -21,736,304 -18,255,896 
      adjustments to reconcile net income to net cash from operating activities:
    		                                
      deferred revenue
    		    0 -1,657,000 3,560,000                          
      net cash from operating activities
    		 4,445,000 -53,410,000 19,360,000 34,096,000 -8,339,000 -132,983,000 -97,875,000 -169,085,000 -150,155,000 -177,620,000 -140,744,000 -154,417,000 -107,024,000 -111,560,000 -112,499,000 -168,625,000 -128,688,000 -153,314,000 141,979,000 -99,824,000 -94,294,000 -108,349,000 -82,071,683 -53,597,640 -39,905,638 -35,560,484 -44,478,223 -33,132,448 -30,694,877 -22,935,249 -15,532,804 
      capex
    		 -49,000 -8,000 -20,000 0 -90,000 -293,000 -95,000 -47,000 -372,000 -259,000 -851,000 -196,000 -391,000 -86,000 -19,000 -352,000 -248,000 -484,000 -711,000 -3,738,000 -538,000 -435,000 -155,786 -470,047 -192,378 -875,111 0 0 0 0 0 
      free cash flows
    		 4,396,000 -53,418,000 19,340,000 34,096,000 -8,429,000 -133,276,000 -97,970,000 -169,132,000 -150,527,000 -177,879,000 -141,595,000 -154,613,000 -107,415,000 -111,646,000 -112,518,000 -168,977,000 -128,936,000 -153,798,000 141,268,000 -103,562,000 -94,832,000 -108,784,000 -82,227,469 -54,067,687 -40,098,016 -36,435,595 -44,478,223 -33,132,448 -30,694,877 -22,935,249 -15,532,804 
      net (decrease)/ increase in cash, cash equivalents and restricted cash
    		                                
      proceeds from income tax refunds net of income taxes paid
    		     -138,000 257,000                          
      net decrease in cash, cash equivalents and restricted cash
    		  -52,785,000          -20,307,000                    
      loss on conversion of debt
    		           0    0 61,102,000 0 39,487,000              
      loss on disposal of fixed assets
    		       -32,000 133,000 0 19,000                      
      forfeiture of accrued interest in exchange of convertible notes
    		           0    0 2,503,000 0 1,668,000              
      accrued expenses and other liabilities
    		   -1,382,000                             
      proceeds from sale of fixed assets
    		                                
      purchase of available-for-sale securities
    		           0 0 0 -331,863,000 -1,000 1,000 0 -171,281,000 -311,880,000 1,000 -339,769,000 -227,419,000          
      proceeds from maturity of available-for-sale securities
    		           124,980,000 124,980,000 83,320,000 60,000,000 85,000,000 180,000,000 130,000,000 25,000,000 312,500,000 202,500,000            
      proceeds from issuance of common stock, net of issuance costs
    		        0   0 0 0 380,120,000     0 0 -170,000 381,593,000 -658,152 0 -22,740 110,262,000 0 -130,997    
      proceeds from issuance of common stock, pre-funded warrant offering, net of issuance costs
    		                                
      payments for development liability
    		       -31,000,000 0   -18,000,000 0 -11,500,000 -5,000,000                  
      proceeds from issuance of common stock under employee share purchase plan
    		   1,319,000 0   1,624,000 0   1,707,000 0   1,272,000 0   1,054,000 0            
      proceeds from issuance of common stock and pre-funded warrant offering, net of issuance costs
    		          384,387,000                      
      income from remeasurement of development derivative liability
    		               55,192,000 4,219,000 21,180,000 17,084,000 40,090,000 -2,697,000 -2,770,000 68,406,000 4,736,000 263,000 9,104,000 736,000      
      amortization of right of use assets
    		                                
      amortization of discounts for convertible notes, net of financing costs
    		       75,000 75,000 74,000 73,000 73,000 96,000 146,000 144,000 143,000 142,000   5,060,000 4,928,000 3,554,000 1,994,000          
      payments for development derivative liability
    		                                
      effect of exchange rate changes on cash and cash equivalents
    		                       8,300 -15,948 15,966 -3,616 -10,586     
      net increase in cash and cash equivalents
    		                       -82,009,559 144,866,075 881,863 111,979,040 -44,373,152    162,507,681 
      amortization of right-of-use assets
    		        -57,000 -15,000 -22,000  -44,000 -44,000 -17,000  -8,000 6,000 112,000  125,000 27,000 57,000  77,793 76,103 72,725      
      payment of employee tax withholding related to equity-based compensation
    		                                
      convertible notes exchanged for common stock
    		                                
      (payments for)/proceeds from development derivative liability
    		                                
      payments for capped call transactions and associated costs
    		                   0 0   0         
      proceeds from issuance of convertible notes, net of issuance costs
    		                   0 -200,000   -487,762         
      proceeds from exercise of stock options and warrants
    		                                
      net decrease in cash and cash equivalents
    		                             100,908,563 -22,712,552  
      supplemental disclosure of financing activities
    		                                
      loss on early extinguishment of debt
    		                       0 293,083 0 1,208,132      
      amortization of debt discounts
    		                  360,000     0         
      amortization of term loan facility discounts
    		                       0         
      repayment of promissory note
    		                       0         
      repayment of term loan facility
    		                       0 0 0 -21,701,292      
      proceeds from / (payments for) development derivative liability
    		                0                
      2019 convertible notes exchanged for common stock
    		                 0 126,129,000              
      proceeds from development derivative liability
    		                   0 0 0 20,000,000 0 20,000,000 40,000,000 60,000,000      
      non-cash lease expense
    		                                
      amortization of discounts for promissory note
    		                                
      deferred issuance costs
    		                        0 -275,509 -334,462 4,246   -2,664  
      issuance of series e convertible preferred stock, net of issuance costs
    		                               0 
      proceeds from issuance of term loan, net of issuance costs
    		                                
      proceeds from issuance of promissory note, net of issuance costs
    		                                
      proceeds from issuance of stock options and warrants
    		                                
      cash and cash equivalents at beginning of period
    		                       0 0 0 176,267,666 0 0 0 175,643,529  
      cash and cash equivalents at end of period
    		                       -82,009,559 144,866,075 881,863 288,246,706 -44,373,152 -33,198,722 100,908,563 152,930,977  
      supplemental disclosure of non-cash financing activities
    		                                
      conversion of convertible preferred stock to common stock
    		                                
      equity component of convertible notes
    		                                
      amortization of deferred financing costs
    		                                
      accretion of discounts for promissory note
    		                         19,438 18,777 18,744     
      accretion of discounts for term loan facility
    		                         0 104,172 118,955     
      refundable research and development credit
    		                         -212,022 -275,218 -142,453 543,082 -168,431 -531,204 946,204 
      (gain)/income from remeasurement of fair value of warrants
    		                                
      issuance of series d convertible preferred stock, net of issuance costs
    		                                
      proceeds from issuance of promissory note payable to an affiliate of stockholder
    		                                
      proceeds from the issuance of common stock warrants
    		                                
      conversion of series a convertible preferred stock
    		                                
      conversion of series b convertible preferred stock
    		                                
      conversion of series c convertible preferred stock
    		                                
      conversion of series d convertible preferred stock
    		                                
      shares reserved under 2010 equity incentive plan
    		                                
      shares reserved under 2017 equity incentive plan
    		                                
      shares reserved under 2017 employee stock purchase plan
    		                                
      common stock warrants
    		                                
      total
    		                           -533,869 5,444,462 2,411,377 2,709,801 5,046,442 
      income from remeasurement of fair value of warrants
    		                            0 0 5,708  
      unrealized foreign currency loss
    		                                
      proceeds for issuance of series e convertible preferred stock, net of issuance costs
    		                                
      supplemental cash flow information:
    		                                
      accrued research and development
    		                            4,376,707 1,620,430 1,857,970  
      accrued payroll liabilities
    		                            887,926 758,733 703,186  
      other
    		                            179,829 32,214 148,645  
      accretion of discounts
    		                             17,675 17,073  
      amortization of term loan facility
    		                                
      amortization
    		                              208,624  
      non-cash acquisition of in-process research and development
    		                                
      issuance of series c convertible preferred stock, net of issuance costs
    		                                
      cash and cash equivalents beginning of period
    		                                
      cash and cash equivalents end of period
    		                                
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.